Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
AAPG
Valuation N/A
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price$14.55
Model IV—
P/IV—
Market implies +19.4%/yr
AARD
Valuation N/A
Aardvark Therapeutics, Inc.
Price$4.71
Model IV—
P/IV—
Limited data — see page
ABBV
Fairly valued
AbbVie Inc.
Price$272.42
Model IV$249.16
P/IV1.06
Premium +9%
Return to IV: -8.5%
Market implies +7.3%/yr
vs model +7.6% · in line
ABCL
Valuation N/A
AbCellera Biologics Inc.
Price$12.02
Model IV—
P/IV—
Market implies +91.1%/yr
ABEO
Valuation N/A
ABEONA THERAPEUTICS INC.
Price$4.96
Model IV—
P/IV—
Market implies +47.7%/yr
ABT
Fairly valued
ABBOTT LABORATORIES
Price$98.49
Model IV$90.43
P/IV1.12
Premium +9%
Return to IV: -8.2%
Market implies +7.0%/yr
vs model +7.2% · in line
ABUS
Valuation N/A
Arbutus Biopharma Corp
Price$4.18
Model IV—
P/IV—
Market implies +54.9%/yr
ABVC
Valuation N/A
ABVC BIOPHARMA, INC.
Price$0.98
Model IV—
P/IV—
Market implies +65.2%/yr
ABVX
Valuation N/A
Abivax S.A.
Price$89.05
Model IV—
P/IV—
Limited data — see page
ACAD
Deeply overvalued
ACADIA PHARMACEUTICALS INC
Price$19.58
Model IV$8.75
P/IV3.02
Premium +124%
Return to IV: -55.3%
Market implies +21.4%/yr
vs model +13.6% · above model
ACB
Fairly valued
AURORA CANNABIS INC
Price$4.43
Model IV$4.74
P/IV0.90
Discount 7%
Return to IV: +7.1%
Market implies -3.5%/yr
vs model +5.4% · below model
ACET
Valuation N/A
Adicet Bio, Inc.
Price$5.74
Model IV—
P/IV—
Limited data — see page
ACHV
Valuation N/A
ACHIEVE LIFE SCIENCES, INC.
Price$7.19
Model IV—
P/IV—
Limited data — see page
ACIU
Valuation N/A
AC Immune SA
Price$2.55
Model IV—
P/IV—
Market implies +54.5%/yr
ACRS
Valuation N/A
Aclaris Therapeutics, Inc.
Price$3.79
Model IV—
P/IV—
Market implies +49.8%/yr
ACRV
Valuation N/A
Acrivon Therapeutics, Inc.
Price$1.87
Model IV—
P/IV—
Limited data — see page
ACTU
Valuation N/A
ACTUATE THERAPEUTICS, INC.
Price$0.68
Model IV—
P/IV—
Limited data — see page
ACXP
Valuation N/A
Acurx Pharmaceuticals, Inc.
Price$1.25
Model IV—
P/IV—
Limited data — see page
ADAG
Valuation N/A
Adagene Inc.
Price$2.78
Model IV—
P/IV—
Market implies +43.6%/yr
ADCT
Deeply overvalued
ADC Therapeutics SA
Price$1.59
Model IV$0.99
P/IV1.29
Premium +61%
Return to IV: -38.0%
Market implies +4.9%/yr
vs model +24.5% · below model
ADIL
Valuation N/A
ADIAL PHARMACEUTICALS, INC.
Price$3.97
Model IV—
P/IV—
Limited data — see page
ADTX
Valuation N/A
Aditxt, Inc.
Price$0.00
Model IV—
P/IV—
Market implies +60.0%/yr
ADXN
Valuation N/A
Addex Therapeutics Ltd.
Price$3.18
Model IV—
P/IV—
Market implies +93.8%/yr
AEON
Valuation N/A
AEON Biopharma, Inc.
Price$0.31
Model IV—
P/IV—
Limited data — see page
AGIO
Valuation N/A
AGIOS PHARMACEUTICALS, INC.
Price$31.92
Model IV—
P/IV—
Market implies +33.5%/yr
AKAN
Fairly valued
AKANDA CORP.
Price$1.78
Model IV$1.76
P/IV1.83
Premium +1%
Return to IV: -1.0%
Market implies +2.3%/yr
vs model +50.0% · below model
AKBA
Deeply undervalued
Akebia Therapeutics, Inc.
Price$0.81
Model IV$1.92
P/IV0.51
Discount 58%
Return to IV: +135.8%
Market implies -14.8%/yr
vs model +2.0% · below model
AKTS
Valuation N/A
Aktis Oncology, Inc.
Price$17.74
Model IV—
P/IV—
Limited data — see page
AKTX
Valuation N/A
Akari Therapeutics Plc
Price$8.13
Model IV—
P/IV—
Limited data — see page
ALDX
Valuation N/A
Aldeyra Therapeutics, Inc.
Price$0.95
Model IV—
P/IV—
Limited data — see page
ALKS
Undervalued
Alkermes plc.
Price$40.11
Model IV$56.73
P/IV0.71
Discount 29%
Return to IV: +41.4%
Market implies +2.6%/yr
vs model +8.8% · below model
ALLR
Valuation N/A
Allarity Therapeutics, Inc.
Price$0.98
Model IV—
P/IV—
Market implies +53.9%/yr
ALMS
Valuation N/A
ALUMIS INC.
Price$6.97
Model IV—
P/IV—
Market implies +43.3%/yr
ALNY
Fairly valued
ALNYLAM PHARMACEUTICALS, INC.
Price$224.53
Model IV$258.81
P/IV0.99
Discount 13%
Return to IV: +15.3%
Market implies -4.8%/yr
vs model +44.8% · below model
ALT
Valuation N/A
Altimmune, Inc.
Price$2.60
Model IV—
P/IV—
Market implies +139.8%/yr
ALXO
Valuation N/A
ALX ONCOLOGY HOLDINGS INC
Price$1.18
Model IV—
P/IV—
Limited data — see page
ALZN
Valuation N/A
Alzamend Neuro, Inc.
Price$1.34
Model IV—
P/IV—
Limited data — see page
AMLX
Valuation N/A
Amylyx Pharmaceuticals, Inc.
Price$27.20
Model IV—
P/IV—
Market implies +40.7%/yr
AMPH
Deeply undervalued
Amphastar Pharmaceuticals, Inc.
Price$25.81
Model IV$44.06
P/IV0.55
Discount 41%
Return to IV: +70.7%
Market implies +0.6%/yr
vs model +11.0% · below model
AMRN
Valuation N/A
AMARIN CORP PLCUK
Price$11.99
Model IV—
P/IV—
Market implies +35.6%/yr
AMRX
Fairly valued
Amneal Pharmaceuticals, Inc.
Price$19.65
Model IV$17.19
P/IV1.18
Premium +14%
Return to IV: -12.5%
Market implies +9.8%/yr
vs model +10.0% · in line
ANAB
Fairly valued
ANAPTYSBIO, INC
Price$46.21
Model IV$41.67
P/IV1.29
Premium +11%
Return to IV: -9.8%
Market implies -0.7%/yr
vs model +38.8% · below model
ANIP
Deeply undervalued
ANI PHARMACEUTICALS INC
Price$71.98
Model IV$198.38
P/IV0.37
Discount 64%
Return to IV: +175.6%
Market implies +0.5%/yr
vs model +20.1% · below model
ANIX
Valuation N/A
Anixa Biosciences Inc
Price$2.91
Model IV—
P/IV—
Market implies +150.0%/yr
ANL
Valuation N/A
Adlai Nortye Group Ltd.
Price$15.51
Model IV—
P/IV—
Market implies +78.3%/yr
ANNX
Valuation N/A
Annexon, Inc.
Price$4.00
Model IV—
P/IV—
Limited data — see page
ANRO
Valuation N/A
Alto Neuroscience, Inc.
Price$24.03
Model IV—
P/IV—
Limited data — see page
ANTX
Valuation N/A
AN2 Therapeutics, Inc.
Price$4.68
Model IV—
P/IV—
Limited data — see page
ANVS
Valuation N/A
Annovis Bio, Inc.
Price$1.17
Model IV—
P/IV—
Limited data — see page
APLM
Valuation N/A
Apollomics Inc.
Price$21.78
Model IV—
P/IV—
Limited data — see page
APLMW
Valuation N/A
Apollomics Inc.
Price$0.01
Model IV—
P/IV—
Limited data — see page
APRE
Valuation N/A
Aprea Therapeutics, Inc.
Price$0.56
Model IV—
P/IV—
Limited data — see page
APUS
Valuation N/A
Apimeds Pharmaceuticals US, Inc.
Price$5.51
Model IV—
P/IV—
Limited data — see page
APVO
Valuation N/A
Aptevo Therapeutics Inc.
Price$1.80
Model IV—
P/IV—
Market implies -21.6%/yr
AQST
Valuation N/A
Aquestive Therapeutics, Inc.
Price$4.76
Model IV—
P/IV—
Market implies +38.7%/yr
ARCT
Deeply overvalued
Arcturus Therapeutics Holdings Inc.
Price$12.87
Model IV$9.83
P/IV1.44
Premium +31%
Return to IV: -23.6%
Market implies +8.2%/yr
vs model +50.0% · below model
ARDX
Deeply undervalued
ARDELYX, INC.
Price$3.27
Model IV$11.13
P/IV0.31
Discount 71%
Return to IV: +240.4%
Market implies -20.9%/yr
vs model +50.0% · below model
ARQT
Deeply overvalued
Arcutis Biotherapeutics, Inc.
Price$24.49
Model IV$5.84
P/IV4.53
Premium +319%
Return to IV: -76.2%
Market implies +17.4%/yr
vs model +15.0% · in line
ARTL
Valuation N/A
ARTELO BIOSCIENCES, INC.
Price$3.37
Model IV—
P/IV—
Limited data — see page
ARVN
Deeply undervalued
ARVINAS, INC.
Price$7.51
Model IV$23.24
P/IV0.33
Discount 68%
Return to IV: +209.5%
Market implies -19.2%/yr
vs model +48.8% · below model